A STAT Investigation: Inside a secretive partnership between IQVIA and Experian

The investigation found privacy lapses in IQVIA's long-running relationship with the credit reporting firm Experian. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     Internal documents show privacy lapses at a data powerhouse that holds health records and consumer information on millions of Americans By Casey Ross CASEY SHENERY FOR STAT To the outside world and its countless health care customers, the data powerhouse IQVIA has portrayed itself as a bastion of privacy. But internal documents reveal a different reality. A STAT investigation found privacy lapses in the company’s secretive and long-running relationship with the credit reporting firm Experian, whose detailed consumer data it buys and then links with Americans’ health records — all to deliver marketing insights to drug companies and device makers. Read More Sponsored by Wheel STAT E-Book: How technology is changing the face of medicine The 2022 STAT Health Tech Summit brought together the most prominent leaders working at the intersection of health and technology. Our latest e-book lays out the most pressing issues in health care that tech could help solve, the exciting new ideas to make that happen, and the barriers to pulling them off. Download now. More great reads from STAT this week Two deadly days in St. Louis: An overdose cluster kills 8 Black people — and shows the new shape of the addiction crisis By Andrew Joseph Encouraged by right-wing doctor groups, desperate patients turn to ivermectin for long Covid By Olivia Goldhill Drawing on therapy developed to save soldiers, an app aims to prevent suicide in those at highest risk By Mario Aguilar ‘No magic bullet’: For drugmakers and the FDA, clinical trials on ultra-rare diseases pose thorny challenges By Ed Silverman Opinion: Value-based payment has produced little value. It needs a time-out By Kip Sullivan, Ana Malinow, and Kay Tillow A troubling report on Cerner’s VA rollout offers a rare look into the hidden harms of health records By Katie Palmer Four brain-computer interface companies you should watch (other than Neuralink) By Elissa Welle ‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing By Rachel Cohrs ​​Genomics is racing toward a $100 genome. Are we ready for it? By Jonathan Wosen Saturday, July 30, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser